United Therapeutics (UTHR) traded higher after releasing first-quarter 2026 financial results before the market open on May 6, 2026, and emphasizing pipeline momentum that could expand future growth drivers. Management pointed to positive results from the ADVANCE OUTCOMES and TETON-1 studies and introduced development plans for ralinepag DPI, a next-generation program the company believes could support broader pulmonary indications and potentially once-daily dosing. (ir.unither.com)

For the quarter ended March 31, 2026, United Therapeutics reported total revenue of $781.5 million (down 2% year over year) and net income of $274.9 million, with diluted EPS of $5.82. The release also disclosed a lower effective tax rate (14%) versus the prior-year quarter and noted unrealized losses in equity securities within other expense. (ir.unither.com)

Beyond the quarter’s financials, the company framed today’s update around clinical execution: it highlighted the ADVANCE OUTCOMES and TETON-1 results and positioned them as potential levers for revenue diversification. United Therapeutics also said it is moving forward with development plans for ralinepag DPI, aiming to extend its footprint across pulmonary hypertension and fibrotic lung diseases. (ir.unither.com)

Investors are also weighing the company’s ongoing repurchase activity: the filing notes a board-authorized program of up to $2.0 billion that expires March 9, 2027, including accelerated share repurchase agreements totaling about $1.5 billion, with $500 million remaining available as of March 31, 2026. The next near-term swing factors are management commentary on the webcast scheduled for 9:00 a.m. ET and any additional detail on the path back to sequential quarterly revenue growth across the commercial portfolio. (ir.unither.com)